文献速递静脉血栓栓塞

癌症合并近端深静脉血栓:导管定向溶栓与抗凝的院内结局比较

In-hospital outcomes of catheter-directed thrombolysis versus anticoagulation in cancer patients with proximal deep venous thrombosis.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2019-12-14

本研究利用美国全国住院患者样本数据库,纳入2005年1月至2013年12月因下肢近端或腔静脉DVT入院的癌症患者31,124例,其中1,290例(4%)接受CDT。倾向性评分匹配后每组1,297例,CDT联合抗凝与单用抗凝相比院内死亡率无显著差异(2.6% vs 1.9%;P = .23),但CDT与颅内出血、输血、操作相关血肿、住院时间和费用增加相关。

要点

  • 癌症合并近端DVT患者中,CDT联合抗凝与单用抗凝的院内死亡率无显著差异。
  • CDT与颅内出血、输血率和操作相关血肿风险增加相关。
  • CDT组住院时间更长、住院费用更高,需权衡获益与资源利用。

核心结论

  • 癌症合并近端DVT患者接受CDT联合抗凝与单用抗凝相比,院内死亡率无显著差异。
  • CDT与院内并发症发生率和资源利用增加相关。

研究设计与样本

  • 观察性研究,使用美国全国住院患者样本数据库筛选2005年1月至2013年12月因下肢近端或腔静脉DVT入院的癌症患者。
  • 共识别31,124例癌症合并下肢近端或腔静脉DVT患者,其中1,290例(4%)接受CDT。
  • 采用倾向性评分匹配 comorbidities 和人口学特征后,比较每组1,297例患者的结局。

主要发现

  • 匹配后CDT联合抗凝组与单用抗凝组院内死亡率分别为2.6%和1.9%(P = .23),无显著差异。
  • CDT组颅内出血发生率1.3%,单用抗凝组0.4%(P = .017)。
  • CDT组输血率18.6%,单用抗凝组13.1%(P < .001)。
  • CDT组操作相关血肿发生率2.4%,单用抗凝组0.4%(P < .001)。
  • CDT组住院时间6.0(4.0-10.0)天,单用抗凝组4.0(2.0-7.0)天(P < .001);住院费用分别为$81,535($50,968-$127,045)和$22,320($11,482-$41,005)(P < .001)。

临床怎么用

  • 对癌症合并近端DVT患者选择CDT前应充分评估出血风险及预期获益。
  • CDT可能增加颅内出血、输血和血肿风险,并延长住院时间、增加费用。

局限性

  • 本研究为观察性数据库分析,可能存在未测量混杂因素。
  • 原文未报告CDT对血栓后综合征(PTS)的影响,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The objective of this study was to determine the rate of complications of catheter-directed thrombolysis (CDT) in cancer patients with deep venous thrombosis (DVT) compared with anticoagulation therapy alone. METHODS: This observational study used the National Inpatient Sample database to screen for any cancer patients who were admitted with a principal discharge diagnosis of proximal lower extremity or caval DVT between January 2005 and December 2013. Patients treated with CDT plus anticoagulation were compared with those treated with anticoagulation alone using propensity score matching for comorbidities and demographic characteristics. The primary end point was in-hospital mortality. Secondary end points were acute intracranial hemorrhage, inferior vena cava filter placement, acute renal failure, blood transfusion rates, length of stay, and hospital charges. RESULTS: We identified 31,124 cancer patients with lower extremity proximal or caval DVT, and 1290 (4%) patients were treated with CDT. Comparative outcomes as assessed in the two matched groups of 1297 patients showed that there was no significant difference in in-hospital mortality of patients undergoing CDT plus anticoagulation compared with those treated with anticoagulation alone (2.6% vs 1.9%; P = .23). However, CDT was associated with increased risk of intracranial hemorrhage (1.3% vs 0.4%; P = .017), greater blood transfusion rates (18.6% vs 13.1 %; P < .001), and higher rates of procedure-related hematoma (2.4% vs 0.4%; P < .001). The length of stay (6.0 [4.0-10.0] days vs 4.0 [2.0-7.0] days; P < .001) and hospital charges ($81,535 [$50,968-$127,045] vs $22,320 [$11,482-$41,005]; P < .001) were also higher in the CDT group compared with the control group. CONCLUSIONS: There was no significant difference in in-hospital mortality of cancer patients who underwent CDT plus anticoagulation compared with anticoagulation alone. CDT was associated with increased in-hospital morbidity and resource utilization compared with anticoagulation alone. Further studies are needed to examine the effect of CDT on the development of PTS in this population.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Brailovsky Y, Yeung HM, Lakhter V, et al. In-hospital outcomes of catheter-directed thrombolysis versus anticoagulation in cancer patients with proximal deep venous thrombosis. J Vasc Surg Venous Lymphat Disord. 2019. PMID: 31843480. doi:10.1016/j.jvsv.2019.10.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。